RxDoctor Payments DataLook up a doctor →

Rafael Perez, MD

Internal Medicine · Manati, PRNPI 1659364644

Payments from drug & device makers

$65,228in general payments, 2019–2025

Across 708 payments — averaging $92.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$47K
  • Johnson & Johnson$4K
  • AstraZeneca$2K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Genentech USA, Inc.$1K
  • Merck$954
  • plus $7K from 40 others

What the payments were for

  • Consulting fees$2,04011%
  • Food & beverage$15,51787%
  • Education$3662%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$65,228 in reported general payments places this provider in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$391,424
Medicare patients
31
Services billed
13,410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib83$1,324,074
RevlimidLenalidomide47$862,080
VerzenioAbemaciclib47$727,980
XtandiEnzalutamide40$574,202
ImbruvicaIbrutinib41$558,126
SprycelDasatinib28$358,978
PomalystPomalidomide12$270,857
StivargaRegorafenib14$245,880
ReblozylLuspatercept-Aamt21$225,704
NubeqaDarolutamide12$170,060
ErleadaApalutamide11$165,135
VenclextaVenetoclax14$157,729
ProliaDenosumab24$42,887
FulphilaPegfilgrastim-Jmdb12$29,556
EliquisApixaban42$26,172

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis, Retacrit$47,349$1,369,426142 claims
Bristol Myers SquibbRevlimid$153$862,08047 claims
E.r. Squibb & Sons, L.L.C.Sprycel, Pomalyst, Reblozyl$1,987$855,53961 claims
Lilly USA, LLCVerzenio$20$727,98047 claims
BayerStivarga, Nubeqa$203$415,94126 claims
Johnson & JohnsonErleada, Xarelto$3,848$177,98733 claims
AbbVieVenclexta, Synthroid$513$160,01759 claims
AmgenProlia$590$42,88724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in Manati

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →